Neue Aspekte zur Therapie des Dravet-Syndroms

Susanne Schubert-Bast; Adam Strzelczyk

doi:10.1055/a-1908-5561

Kinder- und Jugendmedizin, Inhaltsverzeichnis

Kinder- und Jugendmedizin 2022; 22(05): 324-332
DOI: 10.1055/a-1908-5561

Schwerpunkt

Neue Aspekte zur Therapie des Dravet-Syndroms

New aspects for the therapy of Dravet syndrome

Susanne Schubert-Bast

¹Epilepsiezentrum Frankfurt Rhein-Main und Zentrum der Neurologie und Neurochirurgie, Goethe-Universität Franfurt, Frankfurt am Main

²LOEWE Center for Personalized Translational Epilepsy Research (CePTER), Goethe-Universität Frankfurt, Frankfurt am Main

³Klinik für Kinder- und Jugendmedizin, Abt. Neuropädiatrie, Goethe-Universität Frankfurt, Frankfurt am Main

,

Adam Strzelczyk

¹Epilepsiezentrum Frankfurt Rhein-Main und Zentrum der Neurologie und Neurochirurgie, Goethe-Universität Franfurt, Frankfurt am Main

²LOEWE Center for Personalized Translational Epilepsy Research (CePTER), Goethe-Universität Frankfurt, Frankfurt am Main

› Institutsangaben

Abstract

ZUSAMMENFASSUNG

Das Dravet-Syndrom ist gekennzeichnet durch eine schwer behandelbare Epilepsie und assoziierte Komorbiditäten. Nun stehen neben Stiripentol mit Cannabidiol und Fenfluramin zwei neue und spezifische Therapieoptionen zur Verfügung. In diesem Beitrag erfolgt ein Überblick über die gebräuchlichsten und neuen Antikonvulsiva, deren Wirkung, Sicherheitsprofil sowie die potenziellen Interaktionen.

ABSTRACT

Dravet syndrome is characterized by drug resistant epilepsy and associated comorbidities. In addition to stiripentol, cannabidiol and fenfluramine are now available as new and specific therapeutic options. In this review, we provide an overview of the most common and new anticonvulsants, and their efficacy, safety profile, and potential interactions.

Schlüsselwörter

Dravet-Syndrom - Therapie - epileptische Enzephalopathien

Keywords

Dravet-syndrome - therapy - epileptic encephalopathy

Volltext

Referenzen

Literatur
1 Strzelczyk A, Schubert-Bast S. Therapeutic advances in Dravet syndrome: a targeted literature review. Expert Review of Neurotherapeutics 2020: 1-15
2 Strzelczyk A, Schubert-Bast S, Bast T. et al A multicenter, matched case-control analysis comparing burden-of-illness in Dravet syndrome to refractory epilepsy and seizure remission in patients and caregivers in Germany. Epilepsia 2019; 60: 1697-1710
3 Strzelczyk A, Kurlemann G, Bast T. et al Exploring the relationships between composite scores of disease severity, seizure-freedom and quality of life in Dravet syndrome. Neurol Res Pract 2022; 04: 22
4 Dravet C. The core Dravet syndrome phenotype. Epilepsia 2011; 52 (Suppl. 02) 3-9
5 Selvarajah A, Zulfiqar-Ali Q, Marques P. et al A systematic review of adults with Dravet syndrome. Seizure 2021; 87: 39-45
6 Shmuely S, Sisodiya SM, Gunning WB. et al Mortality in Dravet syndrome: A review. Epilepsy Behav 2016; 64: 69-74
7 Schubert-Bast S, Kay L, Simon A. et al Epidemiology, healthcare resource use, and mortality in patients with probable Dravet syndrome: A population-based study on German health insurance data. Epilepsy Behav 2021; 126: 108442
8 Schubert-Bast S, Wolff M, Wiemer-Kruel A. et al Seizure management and prescription patterns of anticonvulsants in Dravet syndrome: A multicenter cohort study from Germany and review of literature. Epilepsy Behav 2019; 98: 88-95
9 Nalivaeva NN, Belyaev ND, Turner AJ. Sodium valproate: an old drug with new roles. Trends Pharmacol Sci 2009; 30: 509-514
10 Research C for DE and. Valproate Information. FDA 2019
11 Gauthier AC, Mattson RH. Clobazam: A Safe, Efficacious, and Newly Rediscovered Therapeutic for Epilepsy. CNS Neurosci Ther 2015; 21: 543-548
12 Frisium 10 mg Tablets – Summary of Product Characteristics (SmPC) – (emc). Im Internet. https://www.medicines.org.uk/emc/product/1574/smpc#gref Stand: 25.06.2022
13 Nickels KC, Wirrell EC. Stiripentol in the Management of Epilepsy. CNS Drugs 2017; 31: 405-416
14 Fisher JL. Interactions between modulators of the GABA(A) receptor: Stiripentol and benzodiazepines. Eur J Pharmacol 2011; 654: 160-165
15 Wirrell EC, Laux L, Franz DN. et al Stiripentol in Dravet syndrome: results of a retrospective U. S. study. Epilepsia 2013; 54: 1595-1604
16 May TW, Boor R, Mayer T. et al Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit 2012; 34: 390-397
17 Zulfiqar Ali Q, Marques P, Selvarajah A. et al Starting stiripentol in adults with Dravet syndrome? Watch for ammonia and carnitine. Epilepsia 2020; 61: 2435-2441
18 Diacomit 250 mg powder for oral suspension in sachet – Summary of Product Characteristics (SmPC) – (emc). Im Internet. https://www.medicines.org.uk/emc/product/10304/smpc Stand: 25.06.2022
19 Gray RA, Whalley BJ. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord 2020; 22: 10-15
20 D’Onofrio G, Kuchenbuch M, Hachon-Le Camus C. et al Slow Titration of Cannabidiol Add-On in Drug-Resistant Epilepsies Can Improve Safety With Maintained Efficacy in an Open-Label Study. Front Neurol 2020; 11: 829
21 Abu-Sawwa R, Stehling C. Epidiolex (Cannabidiol) Primer: Frequently Asked Questions for Patients and Caregivers. J Pediatr Pharmacol Ther 2020; 25: 75-77
22 Epidyolex 100 mg/ml oral solution – Summary of Product Characteristics (SmPC) – (emc). Im Internet. https://www.medicines.org.uk/emc/product/10781/smpc Stand: 25.06.2022
23 Lattanzi S, Trinka E, Striano P. et al Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis. Epilepsia 2020; 61: 1090-1098
24 Fintepla 2.2 mg/mL oral solution – Summary of Product Characteristics (SmPC) – (emc). Im Internet. https://www.medicines.org.uk/emc/product/11998/smpc Stand: 25.06.2022
25 Schoonjans A-S, Ceulemans B. An Old Drug for a New Indication: Repurposing Fenfluramine From an Anorexigen to an Antiepileptic Drug. Clin Pharmacol Ther 2019; 106: 929-932
26 Ceulemans B, Boel M, Leyssens K. et al Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia 2012; 53: 1131-1139
27 Boyd B, Smith S, Gammaitoni A. et al A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects. Int J Clin Pharmacol Ther 2019; 57: 11-19
28 Schoonjans A-S, Ceulemans B. A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome. Expert Rev Neurother 2022; 22: 351-364
29 Martin P, de Witte PAM, Maurice T. et al Fenfluramine acts as a positive modulator of sigma-1 receptors. Epilepsy Behav 2020; 105: 106989
30 Lai WW, Galer BS, Wong PC. et al Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long-term open-label safety extension study. Epilepsia 2020; 61: 2386-2395
31 Strzelczyk A, Pringsheim M, Mayer T. et al Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany. Epilepsia 2021; 62: 2518-2527
32 Topamax 25 mg Tablets – Summary of Product Characteristics (SmPC) – (emc). Im Internet. https://www.medicines.org.uk/emc/product/1442/smpc Stand: 25.06.2022
33 Albsoul-Younes AM, Salem HA, Ajlouni SF. et al Topiramate slow dose titration: improved efficacy and tolerability. Pediatr Neurol 2004; 31: 349-352
34 Bast T, Steinhoff BJ.. Anticonvulsant Agents: Potassium Bromide. In: Riederer P, Laux G, Mulsant B, et al. (Hrsg). NeuroPsychopharmacotherapy. Cham: Springer International Publishing; 2020: 1-7
35 Lotte J, Haberlandt E, Neubauer B. et al Bromide in patients with SCN1A-mutations manifesting as Dravet syndrome. Neuropediatrics 2012; 43: 17-21